clinical trial · NCT07141511
A Study to Investigate the Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet Containing Zanubrutinib and Sonrotoclax (BG-71332) in Healthy Adults
BeOne Medicines·phase1·completed·n = 24
Healthy VolunteersBG-71332ZanubrutinibSonrotoclax
brief summary
The purpose of this study is to evaluate the relative bioavailability of a fixed-dose combination tablet containing zanubrutinib and sonrotoclax (BG-71332) compared to a zanubrutinib capsule and sonrotoclax tablet administered simultaneously and the effect of food on how the body processes the fixed-dose combination tablet.
started
Sep 24, 2025
primary completion
Feb 23, 2026
completion
Feb 23, 2026
last updated
Apr 22, 2026
official title
A Phase 1, Single-dose, Open-label, Randomized, Crossover Study in Healthy Adult Participants to Evaluate Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet Containing Zanubrutinib and Sonrotoclax (BG-71332)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol